infections
Microbiota-based approaches could help researchers expand the therapeutic toolkit for fighting antibiotic resistance and treating tough infections.
Christophe Roca, Head of Pilot Department at Sacco System, talks about development and GMP production of Live Biotherapeutics for all applications.
Juan Basterra, CEO at Mikrobiomik, talks about the interim results on MBK-01, the first intestinal microbiota-based biological drug in phase 3 for both primary episode and recurrence of Clostridioides dificile.
The findings of a recent study suggest that combining Lactobacillus probiotics with nanozymes can help treat Candida vaginitis and help the growth of beneficial vaginal microbes.
The findings of a recent study suggest that a mild gastrointestinal infection can alter gut commensal populations in ways that boost the commensal’s ability to proliferate during an infection.
The findings of a recent study may help to develop diagnostic or therapeutic approaches to reduce bacterial bloodstream infections in newborns.
An altered metasystem linking the gut microbiota and systemic immune response could lead to impaired host defense and increased vulnerability to hospital-acquired infections in cases of severe illness.
Diet-induced changes in the gut microbiota confer protection against respiratory infections by regulating the development of key components of the immune system.
Microbiomepost discussed with Vanessa Harris during the MicrobiotaMI congress 2023 about viral interaction with gut microbiome.
Lactobacillus plantarum P 17630 has obtained marketing authorization from the health authorities of the first group of EU states for the topical vaginal drug in soft and hard capsules.
